Gemcitabine does not prevent acute rejection of the transplanted liver in rats

Transpl Int. 2005 Jan;17(11):687-91. doi: 10.1007/s00147-004-0752-1. Epub 2004 Dec 3.

Abstract

Our study was designed to determine effect of gemcitabine on acute rejection of liver in rats. Liver transplantation was performed in rats of the Dark Agouti (DA) and Lewis (LEW) strains. Recipients were divided into three groups: A, DA-to-LEW without immunosuppression; B, DA-to-LEW, treated with cyclosporine A; C, DA-to-LEW, treated with gemcitabine. Immunosuppressants were subcutaneously injected for seven consecutive days after transplantation. On day 7, blood samples and liver graft tissue specimens were harvested. Group A showed severe rejection changes (RAI 8/9); in group B no rejection changes were present (RAI 0/9), and in group C moderate rejection changes were observed (RAI 6/9). Differences were significant between B vs C and A vs C groups; P<0.05. Serum creatinine and urea levels in the gemcitabine group were significantly lower than those in the cyclosporine A group. We did not confirm gemcitabine ability to prevent liver allograft rejection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Creatinine / blood
  • Cyclosporine / pharmacology
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology*
  • Gemcitabine
  • Graft Rejection / pathology
  • Graft Rejection / prevention & control*
  • Immunosuppressive Agents / pharmacology*
  • Liver / pathology
  • Liver Transplantation*
  • Male
  • Rats
  • Rats, Inbred Lew
  • Rats, Inbred Strains
  • Treatment Failure
  • Urea / blood

Substances

  • Immunosuppressive Agents
  • Deoxycytidine
  • Cyclosporine
  • Urea
  • Creatinine
  • Gemcitabine